{"entity":{"id":"atxn1l","kind":"target","name":"ATXN1L","aka":["ataxin 1 like","Ataxin-1-like","BOAT1"],"tldr":"ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.","summary":"Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1).\n\nCIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Vemurafenib, Trametinib and Dabrafenib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:33279","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33279"},{"label":"UniProt P0C7T5","url":"https://www.uniprot.org/uniprotkb/P0C7T5/entry"},{"label":"NCBI Gene 342371","url":"https://www.ncbi.nlm.nih.gov/gene/342371"},{"label":"Ensembl ENSG00000224470","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000224470"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["pancreatic","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ATXN1L","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:33279","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:33279","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P0C7T5","url":"https://www.uniprot.org/uniprotkb/P0C7T5/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ATXN1L","url":"https://civicdb.org/features/22231","note":"2 evidence items, 0 assertions, 1 variants; diseases: Melanoma, Pancreatic Cancer (GraphQL API, CC0)"}],"hgnc":"HGNC:33279","ensembl":"ENSG00000224470","uniprot":"P0C7T5","entrez":"342371","biology":"Chromatin-binding factor that repress Notch signalling in the absence of Notch intracellular domain by acting as a CBF1 corepressor. Binds to the HEY promoter and might assist, along with NCOR2, RBPJ-mediated repression. Can suppress ATXN1 cytotoxicity in spinocerebellar ataxia type 1 (SCA1). In concert with CIC and ATXN1, involved in brain development. Location: Nucleus; Cell projection, dendrite (UniProt). Locus 16q22.2 (HGNC).","whereFound":["Pancreatic ductal adenocarcinoma: CIViC evidence names this disease","Melanoma: CIViC evidence names this disease"],"targetClass":"transcription","prevalence":[]},"route":"/targets/atxn1l/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}